[8-K] Immix Biopharma, Inc. Reports Material Event

Rhea-AI Filing Summary

Immix Biopharma, Inc. (IMMX) filed a current report to update the audit firm consents tied to its existing shelf registration. The company obtained new consents dated November 26, 2025 from KMJ Corbin & Company LLP, its former independent registered public accounting firm, and Crowe LLP, its current independent registered public accounting firm. These consents allow the firms’ audit reports dated March 29, 2024 and March 24, 2025 on Immix Biopharma’s consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2024 to be incorporated by reference into the company’s effective Form S-3 registration statement (No. 333-290725) and referenced under the “Experts” section of the related prospectus. The filing does not announce new operating results or business transactions and is primarily an administrative update supporting ongoing use of the existing registration statement.

false 0001873835 0001873835 2025-11-26 2025-11-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 26, 2025

IMMIX BIOPHARMA, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		001-41159		45-4869378
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

11400 West Olympic Blvd., Suite 200

Los Angeles, CA 90064

(Address of principal executive offices)

(310) 651-8041

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Securities registered pursuant to Section 12(b)of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value of $0.0001 per share		IMMX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

This Current Report on Form 8-K is being filed solely to file newly dated consents of KMJ Corbin & Company LLP, formerly the independent registered public accounting firm of Immix Biopharma, Inc. (the “Company”), and Crowe LLP, currently the independent registered accounting firm of the Company, each dated November 26, 2025, to the incorporation by reference of their reports dated March 29, 2024, and March 24, 2025, respectively, relating to the consolidated financial statements of the Company included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (the “Form 10-K”) filed with the Securities and Exchange Commission on March 25, 2025, into the Company’s Registration Statement on Form S-3 (No. 333-290725)(the “Registration Statement”), as well as the reference to each of KMJ Corbin & Company LLP and Crowe LLP, under the heading “Experts” in the prospectus included as part of the Registration Statement. The updated consents discussed above are filed as Exhibits 23.2 and 23.1 hereto, respectively, and are incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Number		Description
23.1		Consent of Crowe LLP
23.2		Consent of KMJ Corbin & Company LLP
104		Cover Page Interactive Data File (embedded within Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Immix Biopharma, Inc.
Dated: November 26, 2025	/s/ Ilya Rachman
	Ilya Rachman, Ph.D., M.D.
	Chief Executive Officer

FAQ

What is the purpose of Immix Biopharma's (IMMX) latest Form 8-K?

The Form 8-K updates auditor consents so that the audit reports of KMJ Corbin & Company LLP and Crowe LLP on Immix Biopharma's consolidated financial statements can continue to be incorporated by reference into the company's effective Form S-3 registration statement No. 333-290725 and cited under the “Experts” section of the related prospectus.

Which audit firms are involved in this Immix Biopharma (IMMX) 8-K filing?

The filing involves KMJ Corbin & Company LLP, Immix Biopharma's former independent registered public accounting firm, and Crowe LLP, its current independent registered public accounting firm. Both firms provided newly dated consents allowing their prior audit reports to be used in connection with the company’s Form 10-K and Form S-3 registration statement.

Which financial statements are covered by the updated consents for IMMX?

The updated consents cover the consolidated financial statements of Immix Biopharma included in its Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 25, 2025. The audit reports on these statements, dated March 29, 2024 and March 24, 2025, are now formally consented for incorporation into the Form S-3.

How does this 8-K relate to Immix Biopharma's Form S-3 registration statement?

The 8-K supports Immix Biopharma’s Form S-3 registration statement (No. 333-290725) by providing newly dated consents from both KMJ Corbin & Company LLP and Crowe LLP. These consents permit the continued incorporation by reference of their audit reports and allow the firms to be listed under the “Experts” section in the Form S-3 prospectus.

Does the Immix Biopharma (IMMX) 8-K announce any new financial results or business deals?

No. The 8-K is described as being filed solely to provide updated consents from Immix Biopharma’s former and current independent registered public accounting firms for use in its Form S-3 registration statement and related prospectus. It does not disclose new operating results, financing transactions, or business agreements.

Who signed the Immix Biopharma Form 8-K and in what capacity?

The Form 8-K was signed on behalf of Immix Biopharma, Inc. by Ilya Rachman, Ph.D., M.D., who is identified as the company’s Chief Executive Officer.